|

Entecavir Clinical Trials

5 actively recruiting trials

▲ +1 trial since August 2026

Also known as: Baraclude, Entecavir Dispersible Tablets

Pipeline

Phase 3: 1Phase 4: 3

Top Sponsors

  • University Health Network, Toronto1
  • Third Affiliated Hospital, Sun Yat-Sen University1
  • Taichung Veterans General Hospital1
  • Sun Yat-sen University1
  • Bangladesh Medical University1

Indications

  • Liver Disease4
  • Hepatitis B3
  • Lung Transplant Recipient1
  • Viral Hepatitis1
  • Acute on Chronic Liver Failure1

Other5 trials

Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors
Phase 4
Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver
Phase 4
Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers
Phase 3
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
Phase 4
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.